Please Wait

Applying Filters...

Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Calcipotriol Monohydrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

47 API Suppliers, 19 USDMF, 11 CEP/COS, 4 EU WC, 1 KDMF, 14 NDC API, 21 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

64 Drugs in Development

64 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

256 FDF Dossiers, 23 FDA Orange Book, 189 Europe, 23 Canada, 8 Australia, 8 South Africa, 5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CREAM;TOPICAL - 0.005%, SOLUTION;TOPICAL - 0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, OINTMENT;TOPICAL - 0.064%;0.005%, SUSPENSION;TOPICAL - 0.064%;0.005%, AEROSOL, FOAM;TOPICAL - 0.005%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 DKSH, 4 Nanjing Well Pharmaceutical, 4 Kirsch Pharma, 3 Actylis, 12 BASF, 1 Corel Pharma Chem, 2 Finar, 1 Pluviaendo, 1 Seppic, 1 Symrise, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

20 Topical, 10 Parenteral, 7 Solubilizers, 5 Thickeners and Stabilizers, 4 Emulsifying Agents, 4 Film Formers & Plasticizers, 3 Lubricants & Glidants, 2 Granulation, 2 Direct Compression, 1 Surfactant & Foaming Agents, 1 Controlled & Modified Release, 1 Fillers, Diluents & Binders

DIGITAL CONTENT

29 News #PharmaBuzz

29 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 US Medicaid Prescriptions, 43 Regulatory FDF Prices, 12 Annual Reports

MARKET PLACE

10 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

18 US Patents, 6 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 Others

$ Xls download

Filters

Log in to download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	TAPI Technology & API Services	Israel	TAPI NL B.V. Amsterdam NL	CEP 2007-223 - Rev 04	Calcipotriol	2025-07-11	Valid	Chemical		2011
29/11/2025	TAPI Technology & API Services	Israel	TAPI NL B.V. Amsterdam NL	CEP 2014-016 - Rev 02	Calcipotriol monohydrate	2025-06-17	Valid	Chemical		2284

Contact us
to update this info

Calcipotriol Monohydrate

Calcipotriol Monohydrate

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

47 API Suppliers

19 USDMF

11 CEP/COS

4 EU WC

1 KDMF

14 NDC API

21 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

64 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

256 FDF Dossiers

23 FDA Orange Book

189 Europe

23 Canada

8 Australia

8 South Africa

5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CREAM;TOPICAL - 0.005%

SOLUTION;TOPICAL - 0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

OINTMENT;TOPICAL - 0.064%;0.005%

SUSPENSION;TOPICAL - 0.064%;0.005%

AEROSOL, FOAM;TOPICAL - 0.005%

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 DKSH

4 Nanjing Well Pharmaceutical

4 Kirsch Pharma

3 Actylis

12 BASF

1 Corel Pharma Chem

2 Finar

1 Pluviaendo

1 Seppic

1 Symrise

1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

20 Topical

10 Parenteral

7 Solubilizers

5 Thickeners and Stabilizers

4 Emulsifying Agents

4 Film Formers & Plasticizers

3 Lubricants & Glidants

2 Granulation

2 Direct Compression

1 Surfactant & Foaming Agents

1 Controlled & Modified Release

1 Fillers, Diluents & Binders

DIGITAL CONTENT

29 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 US Medicaid Prescriptions

43 Regulatory FDF Prices

12 Annual Reports

MARKET PLACE

10 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

18 US Patents

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

1 Others

Filters

SOLUTION;TOPICAL - 0.005% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons